PL3579857T3 - Produkt zastępujący czynnik krzepnięcia krwi do stosowania w leczeniu lub profilaktyce krwawień - Google Patents

Produkt zastępujący czynnik krzepnięcia krwi do stosowania w leczeniu lub profilaktyce krwawień

Info

Publication number
PL3579857T3
PL3579857T3 PL18703026.7T PL18703026T PL3579857T3 PL 3579857 T3 PL3579857 T3 PL 3579857T3 PL 18703026 T PL18703026 T PL 18703026T PL 3579857 T3 PL3579857 T3 PL 3579857T3
Authority
PL
Poland
Prior art keywords
bleedings
prophylaxis
treatment
blood coagulation
coagulation factor
Prior art date
Application number
PL18703026.7T
Other languages
English (en)
Inventor
Oliver GROTTKE
Eva HERZOG
Gerald HOCHLEITNER
Original Assignee
Csl Behring Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csl Behring Gmbh filed Critical Csl Behring Gmbh
Publication of PL3579857T3 publication Critical patent/PL3579857T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21005—Thrombin (3.4.21.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21038—Coagulation factor XIIa (3.4.21.38)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL18703026.7T 2017-02-09 2018-02-09 Produkt zastępujący czynnik krzepnięcia krwi do stosowania w leczeniu lub profilaktyce krwawień PL3579857T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17155420 2017-02-09
PCT/EP2018/053240 WO2018146235A1 (en) 2017-02-09 2018-02-09 A blood coagulation factor replacement product for use in the treatment or prophyl of bleedings

Publications (1)

Publication Number Publication Date
PL3579857T3 true PL3579857T3 (pl) 2022-07-25

Family

ID=58016586

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18703026.7T PL3579857T3 (pl) 2017-02-09 2018-02-09 Produkt zastępujący czynnik krzepnięcia krwi do stosowania w leczeniu lub profilaktyce krwawień

Country Status (13)

Country Link
US (1) US11744880B2 (pl)
EP (1) EP3579857B1 (pl)
JP (1) JP7227905B2 (pl)
KR (1) KR102658958B1 (pl)
CN (1) CN110114074B (pl)
AU (1) AU2018217375B2 (pl)
BR (1) BR112019012772A2 (pl)
CA (1) CA3046406C (pl)
DK (1) DK3579857T3 (pl)
ES (1) ES2913934T3 (pl)
PL (1) PL3579857T3 (pl)
SG (1) SG10201912497WA (pl)
WO (1) WO2018146235A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113929741A (zh) * 2020-06-29 2022-01-14 首都医科大学 华法林-4-O-乙酰-Gly-Pro-Arg-Pro-AA1及其合成、活性和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663164A (en) 1980-01-28 1987-05-05 Baxter Travenol Laboratories, Inc. Aqueous compositions for treating blood clotting factor inhibitors
DE3101752A1 (de) 1981-01-21 1982-08-26 Behringwerke Ag, 3550 Marburg "verfahren zur reinigung der blutgerinnungsfaktoren ii, vii, ix und/oder x und danach hergestellte praeparationen"
DE3336631A1 (de) 1983-10-08 1985-04-18 Behringwerke Ag, 3550 Marburg Verfahren zur pasteurisierung von plasma oder von konzentraten der blutgerinnungsfaktoren ii, vii, ix und x
DE3622642A1 (de) 1986-07-05 1988-01-14 Behringwerke Ag Einkomponenten-gewebekleber sowie verfahren zu seiner herstellung
DK0796623T3 (da) 1996-03-20 2005-08-01 Baxter Ag Farmaceutisk præparat til behandling af blodkoagulationslidelser
AT409334B (de) 1997-09-19 2002-07-25 Immuno Ag Pharmazeutisches präparat enthaltend vitamin k-abhängige einzelfaktoren
CA2514001A1 (en) 2003-01-27 2004-08-12 Sherwin V. Kevy Autologous or homologous coagulant produced from anticoagulated whole blood
FR2946348B1 (fr) 2009-06-05 2011-08-05 Lab Francais Du Fractionnement Procede de preparation d'une composition de complexe prothrombique a haut degre de purete
CN103221061A (zh) 2010-10-06 2013-07-24 米迪缪尼有限公司 用于治疗止血障碍的因子ii以及纤维蛋白原
TWI653047B (zh) 2014-03-14 2019-03-11 百特製藥公司 用於在出血性病症的治療中促進止血的人類凝血酶原及活化因子x的組成物
CA2987209A1 (en) 2015-06-10 2016-12-15 Evonik Rohm Gmbh Process for preparing a powder comprising a human coagulation factor protein and a lactic acid polymer

Also Published As

Publication number Publication date
WO2018146235A8 (en) 2019-05-09
BR112019012772A2 (pt) 2019-12-10
US11744880B2 (en) 2023-09-05
US20190351028A1 (en) 2019-11-21
SG10201912497WA (en) 2020-02-27
CA3046406A1 (en) 2018-08-16
AU2018217375B2 (en) 2024-04-18
CN110114074B (zh) 2024-05-28
EP3579857A1 (en) 2019-12-18
EP3579857B1 (en) 2022-04-06
KR20190111912A (ko) 2019-10-02
AU2018217375A1 (en) 2019-06-27
ES2913934T3 (es) 2022-06-06
DK3579857T3 (da) 2022-06-07
KR102658958B1 (ko) 2024-04-22
JP2020506880A (ja) 2020-03-05
JP7227905B2 (ja) 2023-02-22
WO2018146235A1 (en) 2018-08-16
CN110114074A (zh) 2019-08-09
CA3046406C (en) 2024-01-30

Similar Documents

Publication Publication Date Title
AU201810677S (en) Skin treatment article
AU201714140S (en) Skin treatment article
ZA201700459B (en) Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii
AU201714143S (en) Skin treatment article
AU201810686S (en) Skin treatment article
PL3577135T3 (pl) Kompozycja farmaceutyczna do stosowania do leczenia lub zapobiegania chorobom związanym z c5
SI3377637T1 (sl) Sestavki za uporabo pri postopkih za zdravljenje ran, motenj in bolezni kože
IL254142B (en) Tredifitant for use in the treatment of a disease or medical condition that responds to Tredifitent
AU201810683S (en) Skin treatment article
AU201810685S (en) Skin treatment article
AU201714141S (en) Skin treatment article
AU201810689S (en) Skin treatment article
AU201810687S (en) Skin treatment article
GB2542155B (en) Use of cannabidiol in the treatment of mental disorders
LT3197290T (lt) Žuvų pašaras ir jo panaudojimas salmonidae šeimos lašišų jauniklių rituolių (smoltas) hemoraginio sindromo (hhs) profilaktikai ir gydymui
HK1257240A1 (zh) 預防和治療脂肪異常沉積導致的組織損傷的藥物及其用途
HUE051875T2 (hu) Egyláncú oligonukleotidok bõrrendellenességek orvosi kezelésében történõ alkalmazásra
GB201519557D0 (en) Compounds for use in the treatment of telomere related diseases and/or telomere related medical conditions
EP3518951C0 (en) COMPOSITIONS FOR USE IN THE TREATMENT OF OSTEOPOROSIS AND Fractures
IL264600B (en) A knife for use in medical treatment
SG10201912497WA (en) A blood coagulation factor replacement product for use in the treatment or prophylaxis of bleedings
ZA201807692B (en) New use of product for skin treatment
IL289371A (en) Methylthioninium for use in the treatment of synaptopathies
IL248428B (en) 3,1-propanedisulfonic acid or its pharmaceutically acceptable salt for use in the treatment of sarcoidosis
ZA202006886B (en) R-fadrozole for use in the treatment of aldostonerism